Global Survey of Extensively Drug-Resistant Tuberculosis Cases, 2000-2004

17,690 TB isolates were analyzed in a global survey by CDC and WHO between 2000 and 2004, finding 20% were multidrug-resistant (MDR) and 2% were extensively drug-resistant (XDR). The report summarizes results from an international network of TB laboratories, highlighting the emergence of XDR TB as a public health threat. Data includes population-based drug susceptibility results from the United States, Latvia, and South Korea.

Use Cases

• Modeling the global prevalence of XDR TB based on the reported 2% rate among isolates
• Analyzing regional variations in drug resistance using data from the United States, Latvia, and South Korea
• Assessing the threat of virtually untreatable TB based on reported resistance to second-line drugs
• Evaluating the effectiveness of drug susceptibility testing standards mentioned in the description

Strengths

• Based on a survey of 17,690 TB isolates, providing a substantial sample size
• Includes specific, quantified results: 20% MDR and 2% XDR prevalence
• Provides comparative population-based data from three distinct countries (U.S., Latvia, South Korea)

Limitations

• Row count and column-level documentation are absent; field semantics must be inferred after download
• Last update date is unknown; freshness unverified
• Data may reflect geographic and temporal bias inherent to the survey's laboratory network and 2000-2004 timeframe

Provenance

Source

CDC and World Health Organization (WHO)

Collection Method

Survey of an international network of TB laboratories

Time Range

2000-2004 (with some country data from 1993-2004)

Geography

Worldwide, with specific data from the United States, Latvia, and South Korea